World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
76
Citations
20550
World Ranking
5050
National Ranking
113

Overview

Elda Tagliabue is affiliated with the Fondazione IRCCS Istituto Nazionale dei Tumori in Italy. Their research primarily spans the fields of biochemistry, genetics, molecular biology, and medicine, with a pronounced focus on oncology, molecular biology, cancer research, immunology, and infectious diseases.

The scientist's work covers various main topics, including:

  • Gut microbiota and health
  • HER2/EGFR in cancer research
  • Cancer cells and metastasis
  • Cancer immunotherapy and biomarkers
  • Cancer, lipids, and metabolism
  • Immune cells in cancer
  • MicroRNA in disease regulation

Some of the recent publications by Elda Tagliabue provide insight into the thematic focus and scientific contributions, featuring:

  • "The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy" (2020), published in Cellular and Molecular Life Sciences
  • "Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer" (2021), published in Cancer Research
  • "Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences" (2021), published in International Journal of Molecular Sciences
  • "Adipocytes in Breast Cancer, the Thick and the Thin" (2020), published in Cells
  • "Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth" (2021), published in iScience

Frequent coauthors collaborating with Tagliabue include:

  • Tiziana Triulzi
  • Serenella M. Pupa
  • Lucia Sfondrini
  • Francesca Bianchi
  • Loris De Cecco

Publications predominantly appear in journals such as:

  • Cancer Research
  • Cancers
  • International Journal of Molecular Sciences
  • Cells
  • Scientific Reports

Best Publications

  • Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation

    Veronica Huber;Chiara Camisaschi;Angela Berzi;Simona Ferro

  • Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2.

    Roberto Gennari;Sylvie Menard;Francesco Fagnoni;Luisa Ponchio

  • Biologic and therapeutic role of HER2 in cancer.

    Sylvie Ménard;Serenella Marja Pupa;Manuela Campiglio;Elda Tagliabue

  • Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy

    Valentina Ciravolo;Veronica Huber;Gaia C. Ghedini;Elisabetta Venturelli

  • Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificity

    S. Miotti;S. Canevari;S. Ménard;D. Mezzanzanica

  • Replacement of Fhit in cancer cells suppresses tumorigenicity

    Zurab Siprashvili;Gabriella Sozzi;Larry D. Barnes;Peter McCue

  • Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome

    A. Bergamaschi;E. Tagliabue;Therese Sorlie;Therese Sorlie;Bjorn Naume

  • New insights into the role of extracellular matrix during tumor onset and progression.

    Serenella M. Pupa;Sylvie Ménard;Stefania Forti;Elda Tagliabue

  • microRNA-205 Regulates HER3 in Human Breast Cancer

    Marilena V. Iorio;Patrizia Casalini;Claudia Piovan;Gianpiero Di Leva

  • Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis

    Francesco Pezzella;Ugo Pastorino;Elda Tagliabue;Salvatore Andreola

  • Role of HER2 gene overexpression in breast carcinoma.

    Sylvie Ménard;Elda Tagliabue;Manuela Campiglio;Serenella M. Pupa

  • Loss of FHIT Function in Lung Cancer and Preinvasive Bronchial Lesions

    Gabriella Sozzi;Ugo Pastorino;Luisa Moiraghi;Elda Tagliabue

  • Triple-negative breast cancer: Present challenges and new perspectives

    Franca Podo;Lutgarde M.C. Buydens;Hadassa Degani;Riet Hilhorst

  • Immunocytochemical markers in stage I lung cancer: relevance to prognosis.

    Ugo Pastorino;Salvatore Andreola;Elda Tagliabue;Francesco Pezzella

  • FOXP3 Expression and Overall Survival in Breast Cancer

    Andrea Merlo;Patrizia Casalini;Maria Luisa Carcangiu;Chiara Malventano

  • Generation of monoclonal antibodies reacting with normal and cancer cells of human breast.

    Sylvie Mènard;Elda Tagliabue;Silvana Canevari;Giuseppe Fossati

  • Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab

    Alessandra Magnifico;Luisa Albano;Stefano Campaner;Domenico Delia

  • Antitumor Activity of the TLR-5 Ligand Flagellin in Mouse Models of Cancer

    Lucia Sfondrini;Anna Rossini;Dario Besusso;Andrea Merlo

  • Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2

    Stefania Varchetta;Nadia Gibelli;Barbara Oliviero;Elena Nardini

  • The 67 kDa laminin receptor as a prognostic factor in human cancer

    Sylvie Ménard;Elda Tagliabue;Maria Ines Colnaghi

Frequent Co-Authors

Sylvie Ménard
Sylvie Ménard University of Milan
Andrea Balsari
Andrea Balsari University of Milan
Maria I. Colnaghi
Maria I. Colnaghi University of Milan
Gabriella Sozzi
Gabriella Sozzi University of Milan
Carlo M. Croce
Carlo M. Croce The Ohio State University
Claudio Tripodo
Claudio Tripodo FIRC Institute of Molecular Oncology
Ugo Pastorino
Ugo Pastorino University of Milan
Mario P. Colombo
Mario P. Colombo Fondazione IRCCS Istituto Nazionale dei Tumori
Silvana Canevari
Silvana Canevari University of Milan
Silvana Pilotti
Silvana Pilotti University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees related to Biology and Biochemistry opens many pathways, particularly in healthcare, medical coding, and administration. For students interested in healthcare leadership, there are a range of online programs offering flexible options, with healthcare mba cost varying widely depending on the institution and program format.

Another promising route is in medical coding and billing. Gaining a certification can lead to several career tracks with varying salary potential. Understanding the differences in roles is important—compare ccs vs cpc salary to see how credentials might impact your earnings and career outlook.

Medical coding is a strong option for graduates seeking remote or flexible work. Entry-level positions offer competitive pay, as detailed in this guide on medical coding salary. If you’re curious whether this is the right fit, consider the benefits and challenges shared in "is medical coding a good job", which outlines both the rewards and the demands of this growing field.

Best Scientists Citing Elda Tagliabue

Trending Scientists

Recently Published Articles